New hope for blood cancer patients with tough fungal infections
NCT ID NCT07559032
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether the drug amphotericin B can treat serious fungal infections that break through in people with blood cancers who are already taking antifungal prevention. About 15 adults will receive the drug for 4-6 weeks and be closely monitored. The goal is to see how well the infection responds and if the drug is safe.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for INVASIVE FUNGAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University People's Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test outsmart deadly fungal infections in blood cancer?
- New antifungal drug shows promise against deadly fungal infections
- Massive study aims to beat deadly fungus in transplant patients
- New drug could shield transplant patients from deadly fungal infections
- Study questions unnecessary antifungal use in intensive care
- Can immune monitoring unlock better treatments for deadly mold infections?